Candriam S.C.A. Mirum Pharmaceuticals, Inc. Call Options Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MIRM
# of Institutions
190Shares Held
54MCall Options Held
177KPut Options Held
167K-
Frazier Life Sciences Management, L.P. Menlo Park, CA6.57MShares$279 Million13.79% of portfolio
-
Janus Henderson Group PLC London, X04.48MShares$190 Million0.09% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.45MShares$146 Million2.37% of portfolio
-
Black Rock Inc. New York, NY3.24MShares$137 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA3.08MShares$130 Million3.81% of portfolio
About Mirum Pharmaceuticals, Inc.
- Ticker MIRM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,751,700
- Market Cap $1.56B
- Description
- Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...